In general, strive to use antibiotics covering a spectrum no ... If oral therapy is possible: Nonsevere: metronidazole 500 mg three-times daily (t.i.d.) orally for 10 days; Severe: vancomycin ...
Antibiotics have served as the mainstay of ... treated during the open-labeled phase with a 10-day course of 0.75% metronidazole gel and in which asymptomatic responders were then randomized ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
GlobalData on MSN11d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
13d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback